Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease

Kronenberg, Florian; Stühlinger, Markus; Trenkwalder, Evi; Geethanjali, Finney S.; Pachinger, Otmar; Eckardstein, Arnold von; Dieplinger, Hans

doi:10.1016/s0735-1097(00)00775-0

Cited by 102 publications

(58 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with these in vitro data, overexpression of ApoA-IV in transgenic mice led to reduced aortic lesions and protection against atherosclerosis [22,23]. These results were recently confirmed by case-control studies in three independent human populations: ApoA-IV plasma concentrations were found to be significantly lower in patients with coronary artery disease as compared to control groups [24,25]; a correlation between plasma ApoA-IV concentrations and atherosclerosis was also observed in patients with kidney failure [26].…”

Section: By the International Society Of Nephrologysupporting

confidence: 66%

See 1 more Smart Citation

Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue

Haiman¹,

Salvenmoser²,

Scheiber³

et al. 2005

Kidney International

Self Cite

View full text Add to dashboard Cite

The immunoreactivity of ApoA-IV observed in kidney tubular cells suggests a direct role of the human kidney in ApoA-IV metabolism. The granular staining pattern probably represents lysosomes degrading ApoA-IV. The additional ApoA-IV localization in distal tubules suggests a rescue function to reabsorb otherwise escaping ApoA-IV in case proximal tubules cannot reabsorb all ApoA-IV. Since no mRNA expression could be detected in any kidney cells, the observed ApoA-IV immunoreactivity represents uptake and not de novo synthesis of ApoA-IV.

show abstract

Section: By the International Society Of Nephrologysupporting

confidence: 66%

“…The usually observed mean ApoA-IV level in the general population measured with our assay is substantially higher (13 to 15 mg/dL) [24,30].…”

Section: Discussionmentioning

confidence: 85%

Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue

Haiman¹,

Salvenmoser²,

Scheiber³

et al. 2005

Kidney International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Apo A-IV is mainly related to cholesterol homeostasis and oxidative protection, and has been associated with the cardioprotective properties of the HDL particle [38]. Although Apo C-III protein is present in HDL, it is also a major protein in VLDL.…”

Section: Discussionmentioning

confidence: 99%

Impact of Virgin Olive Oil and Phenol-Enriched Virgin Olive Oils on the HDL Proteome in Hypercholesterolemic Subjects: A Double Blind, Randomized, Controlled, Cross-Over Clinical Trial (VOHF Study)

et al. 2015

View full text Add to dashboard Cite

The effects of olive oil phenolic compounds (PCs) on HDL proteome, with respect to new aspects of cardioprotective properties, are still unknown. The aim of this study was to assess the impact on the HDL protein cargo of the intake of virgin olive oil (VOO) and two functional VOOs, enriched with their own PCs (FVOO) or complemented with thyme PCs (FVOOT), in hypercholesterolemic subjects. Eligible volunteers were recruited from the IMIM-Hospital del Mar Medical Research Institute (Spain) from April 2012 to September 2012. Thirty-three hypercholesterolemic participants (total cholesterol >200mg/dL; 19 men and 14 women; aged 35 to 80 years) were randomized in the double-blind, controlled, cross-over VOHF clinical trial. The subjects received for 3 weeks 25 mL/day of: VOO, FVOO, or FVOOT. Using a quantitative proteomics approach, 127 HDL-associated proteins were identified. Among these, 15 were commonly differently expressed after the three VOO interventions compared to baseline, with specific changes observed for each intervention. The 15 common proteins were mainly involved in the following pathways: LXR/RXR activation, acute phase response, and atherosclerosis. The three VOOs were well tolerated by all participants. Consumption of VOO, or phenol-enriched VOOs, has an impact on the HDL proteome in a cardioprotective mode by up-regulating proteins related to cholesterol homeostasis, protection against oxidation and blood coagulation while down-regulating proteins implicated in acute-phase response, lipid transport, and immune response. The common observed protein expression modifications after the three VOOs indicate a major matrix effect.Trial RegistrationInternational Standard Randomized Controlled Trials ISRCTN77500181.

show abstract

“…ApoAIV and adiponectin show anti-atherogenic and antioxidative properties and are negatively correlated with cardiovascular disorders1617. Adiponectin probably protects against cardiac remodeling by attenuating myocardial hypertrophy18; furthermore, it also has protective effects against different vascular disorders, such as endothelial dysfunction and hypertension, and inhibits platelet aggregation and inflammation (reviewed by ref.…”

Section: Discussionmentioning

confidence: 99%

iTRAQ-based proteomic analysis of plasma reveals abnormalities in lipid metabolism proteins in chronic kidney disease-related atherosclerosis

Łuczak

Formanowicz

Marczak

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) have a considerably higher risk of death due to cardiovascular causes. Using an iTRAQ MS/MS approach, we investigated the alterations in plasma protein accumulation in patients with CKD and classical cardiovascular disease (CVD) without CKD. The proteomic analysis led to the identification of 130 differentially expressed proteins among CVD and CKD patients and healthy volunteers. Bioinformatics analysis revealed that 29 differentially expressed proteins were involved in lipid metabolism and atherosclerosis, 20 of which were apolipoproteins and constituents of high-density lipoprotein (HDL) and low-density lipoprotein (LDL). Although dyslipidemia is common in CKD patients, we found that significant changes in apolipoproteins were not strictly associated with changes in plasma lipid levels. A lack of correlation between apoB and LDL concentration and an inverse relationship of some proteins with the HDL level were revealed. An increased level of apolipoprotein AIV, adiponectin, or apolipoprotein C, despite their anti-atherogenic properties, was not associated with a decrease in cardiovascular event risk in CKD patients. The presence of the distinctive pattern of apolipoproteins demonstrated in this study may suggest that lipid abnormalities in CKD are characterized by more qualitative abnormalities and may be related to HDL function rather than HDL deficiency.

show abstract

Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease

Abstract: The results of this cross-sectional study demonstrate for the first time an association between low apoA-IV concentrations and CAD in humans and suggest that apoA-IV may play an antiatherogenic role in humans.

Cited by 102 publications

References 32 publications

Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue

Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue

Impact of Virgin Olive Oil and Phenol-Enriched Virgin Olive Oils on the HDL Proteome in Hypercholesterolemic Subjects: A Double Blind, Randomized, Controlled, Cross-Over Clinical Trial (VOHF Study)

iTRAQ-based proteomic analysis of plasma reveals abnormalities in lipid metabolism proteins in chronic kidney disease-related atherosclerosis

Contact Info

Product

Resources

About